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Abstract 
Background:  To evaluate the influence of treatment on health-related quality of life 
(HRQoL) in 919 women with recurrent ovarian cancer enrolled in the TRINOVA-1 study, 
a randomized, placebo-controlled phase 3 study that demonstrated that trebananib 15 
mg/kg QW plus weekly paclitaxel significantly improved PFS compared with placebo 
plus weekly paclitaxel (7.2 versus 5.4 months; hazard ratio, 0.66; 95% CI, 0.57‒0.77; 
P<0.001).  
Patients and Methods:  HRQoL was assessed with the Functional Assessment of 
Cancer Therapy–Ovary (FACT-O; comprising FACT-G and the ovarian cancer–specific 
subscale [OCS]) and EuroQOL EQ-5D instruments before treatment on day 1 of weeks 
1, 5, 9, 13, 17, and every 8 weeks thereafter and at the safety follow-up visit.  A pattern-
mixture model was used to evaluate influence of patient dropout on FACT-O and OCS 
scores over time. 
Results:  834 of 919 randomized patients (91%) had a baseline and ≥1 post-baseline 
HRQoL assessment.  At baseline, scores for all instruments were similar for both arms.  
At 25 weeks mean ± SD changes from baseline were negligible, with mean ± SD 
changes typically <1 unit from baseline: −2.4±16.6 in the trebananib arm and −1.6±15.2 
in the placebo arm for FACT-O, −0.71±5.5 in the trebananib arm and −0.86±4.9 in the 
placebo arm for OCS, and −0.02±0.22 in the trebananib arm and 0.02±0.19 in the 
placebo arm for EQ-5D.  Distribution of scores was similar between treatment arms at 
baseline and over the course of the study.  In pattern-mixture models, there was no 
evidence that patient dropout affected differences in mean FACT-O or OCS scores.  
Edema had limited effect on either FACT-O or OCS scores in patients with grade ≥2 
edema or those with grade 1 or no edema. 
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Conclusions:  Our results demonstrate that the improvement in PFS among patients in 
the trebananib arm in the TRINOVA-1 study was achieved without compromising 
HRQoL. 
Abstract word count: 300 (limit, 300) 
Key words: Trebananib, Recurrent Ovarian Cancer, Health-related Quality of Life, 
Edema 
 
Clinical trial registration:  ClinicalTrials.gov identifier, NCT01204749 
Key Message: "Results from the TRINOVA-1 study of trebananib plus weekly paclitaxel versus 
placebo plus paclitaxel in women with recurrent ovarian cancer demonstrate that the 
improvement in PFS among patients in the trebananib arm  was achieved without compromising 
HRQoL." 
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Introduction 
Angiogenesis is critical for solid tumor growth and metastasis [1].  Angiogenesis 
is regulated by a number of distinct pathways including the vascular endothelial growth 
factor (VEGF) pathway and the angiopoietin axis [2].  In the angiopoietin axis, the 
ligands angiopoietin-1 and angiopoietin-2 interact with the Tie2 receptor, thereby 
initiating the angiogenic switch and promoting neovascularization [2].  Trebananib is an 
investigational peptide-Fc fusion protein that neutralizes the interaction between 
angiopoietin-1 and angiopoietin-2 and the Tie2 receptor, thereby suppressing 
angiogenesis [3]. 
TRINOVA-1 [4] was a randomized, double-blind, placebo-controlled phase 3 
study evaluating weekly trebananib plus paclitaxel in 919 women with recurrent, 
platinum-resistant or partially platinum-sensitive ovarian cancer.  Compared with 
paclitaxel plus placebo, trebananib plus paclitaxel significantly improved the primary 
endpoint of progression-free survival (PFS; 7.2 versus 5.4 months; hazard ratio, 0.66; 
95% CI, 0.57‒0.77; P<0.001) and significantly improved the objective response rate 
(38% versus 30%; P=0.0071) [4].  Most AEs were consistent with those anticipated for 
patients with recurrent ovarian cancer receiving weekly paclitaxel [5].  Edema was the 
most frequent AE with a ≥10% difference in the treatment arm.  Most edema events 
were of grade 1/2; grade 3 edema led to discontinuation of treatment in 8% of patients in 
the trebananib arm versus 1% in the placebo arm [4]. 
When evaluating the benefit of an investigational treatment regimen, it is 
important to consider whether improvements in outcomes occur at the expense of 
patients’ health-related quality of life (HRQoL).  This is particularly relevant for patients 
with recurrent ovarian cancer who undergo radical surgery and multiple rounds of 
cytotoxic chemotherapy during the course of their illness [6].  HRQoL can be significantly 
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disrupted, and there is debate regarding the appropriate balance between benefits of 
treatment and toxicity [7].  In the TRINOVA-1 study, the PFS benefit and objective tumor 
response associated with the combination of trebananib plus paclitaxel must be weighed 
against the risk of toxicity and its potential to compromise HRQoL.  To examine whether 
addition of trebananib to paclitaxel affected HRQoL in TRINOVA-1, the objectives of the 
study included estimation of the effects of trebananib on patient-reported symptoms 
specific to ovarian cancer using the Functional Assessment of Cancer Therapy–Ovary 
(FACT-O) questionnaire and its effects on patient-reported overall health status using 
the EuroQOL EQ-5D questionnaire.  Because edema was more frequent in patients 
receiving trebananib, we also evaluated whether this AE affected HRQoL. 
 
Methods 
Eligibility 
Complete eligibility criteria have been described previously [4].  Briefly, women 
were eligible if they were ≥18 years, had radiographic evidence of disease progression 
<12 months after receiving platinum-based chemotherapy (ie, platinum-free interval [PFI] 
≤12 months), and had evaluable disease per RECIST version 1.1 with modifications [8].  
Patients were excluded if they had received >3 previous lines of chemotherapy; 
platinum-refractory disease; or borderline, mucinous, or clear-cell histology.  Patients 
provided written informed consent; the study protocol and procedures received approval 
from institutional ethics committees. 
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Study Design and Treatment 
Patients were randomized 1:1 to receive intravenous trebananib 15 mg/kg once 
weekly (QW) plus paclitaxel (trebananib arm) or intravenous placebo QW plus paclitaxel 
(placebo arm).  Paclitaxel infusions followed a 4-week treatment cycle and were 
administered during weeks 1, 2, and 3.  Randomization was stratified by PFI (PFI >0 and 
≤6 months/PFI >6 and ≤12 months), presence/absence of measurable disease, and 
geographic region (North America, Western Europe, or Australia/rest of world).  
Treatment was discontinued if patients had disease progression per modified RECIST 
[8], experienced unacceptable toxicity, or withdrew consent.   
PRO and HRQoL Assessments 
To evaluate HRQoL, patients completed the FACT-O and the EuroQoL EQ-5D.  
FACT-O is a 39-item self-report questionnaire consisting of the Functional Assessment 
of Cancer Therapy–General (FACT-G) and ovarian cancer–specific (OCS) subscales. 
The 27-item FACT-G assesses four domains of well-being: physical, social, emotional, 
and functional aspects [9].  The OCS consists of 12 items evaluating symptoms specific 
to ovarian cancer.  For the FACT-G and OCS subscales, respondents rated each item 
on a 5-point Likert scale from 0 (not at all) to 4 (very much) based on their experience 
during the past 7 days.  The OCS yields a combined summary score ranging between 0 
and 48, with higher scores indicative of better HRQoL [9, 10].  
Overall health status was assessed with the EQ-5D.  Respondents completed 
the EQ-5D by indicating their health state in the areas of mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression [11].  Ratings in each domain of the 
EQ-5D were combined to produce a weighted index score, with higher ratings indicating 
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improved overall health status.  Additionally, respondents rated overall health on the EQ-
5D visual analog scale (VAS) from 0 (worst imaginable) to 100 (best imaginable).   
Questionnaires were administered before patients received treatment or 
completed clinical assessments on day 1 of weeks 1, 5, 9, 13, 17; every 8 weeks up to 2 
years, then every 6±1 months thereafter; and at the safety follow-up visit.  The EQ-5D 
was always administered after the FACT-O (ie, FACT-G and OCS).  If an unscheduled 
radiologic assessment coincided with a scheduled HRQoL assessment, completion of 
the HRQoL assessment was postponed until the next visit to ensure the outcome of 
radiologic assessment did not influence HRQoL assessment.  HRQoL questionnaires 
were only administered to women able to complete them independently and for whom 
appropriate translations were available (if necessary).  HRQoL assessments ceased 
after disease progression. 
Statistical Analysis 
Evaluation of HRQoL and ovarian cancer-related symptoms using FACT-O and 
evaluation of overall health status using EQ-5D were prespecified secondary study 
endpoints.  Patients were included in analyses (PRO-evaluable set) if they had a 
baseline and ≥1 post-baseline HRQoL assessment before disease progression per 
modified RECIST [8].  As previously described [4], a pattern-mixture model [12] was 
used to evaluate whether there were changes in FACT-O and OCS scores over time, 
adjusting for dropout (any-cause).  This model stratifies patients by their last completed 
PRO assessment, thereby accounting for data missing not-at-random between dropout 
patterns. 
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Results 
Patient Characteristics 
Overall, 919 patients (trebananib arm, n=461; placebo arm, n=458) were enrolled 
between November 10, 2010, and November 19, 2012.  The PRO-evaluable set 
included 834 (91%) patients.  Baseline demographic/clinical characteristics were similar 
between treatment arms and between the intent-to-treat population and PRO subset 
(Table 1).  Most patients (57%) had a GOG performance score of 0 (fully active, 
unrestricted activities of daily living) and 24% had history of ascites.  Overall, 39% of 
patients had received one previous line of therapy, 38% received two, and 23% received 
three. 
PRO and HRQoL 
Completion rates were high for all questionnaires at baseline and among patients 
who had not progressed at later time points (Figure 1).  Completion rates were 
consistently high throughout the study. 
At baseline, patients in the trebananib and placebo arms reported similar 
mean±SD scores for the FACT-O (trebananib 106.3±20.6; placebo, 106.6±20.7), OCS 
(30.3±5.9; 30.2±6.1), and EQ-5D (0.75±0.20; 0.74±0.24).  At 25 weeks (which 
approximates median PFS time in the study), mean±SD changes from baseline were 
negligible, with changes typically <1 unit from baseline: −2.4±16.6 in the trebananib arm 
and −1.6±15.2 in the placebo arm for FACT-O, −0.71±5.5 in the trebananib arm and 
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−0.86±4.9 in the placebo arm for OCS, and −0.02±0.22 in the trebananib arm and 
0.02±0.19 in the placebo arm for EQ-5D (Figure 2).  Similar patterns were seen for the 
EQ-5D VAS (Supplementary Figure 1).  Subscale scores of the FACT-O provided little 
evidence of differences in patients’ assessment of physical, social, emotional, and 
functional well-being during the first 25 weeks of the study (data not shown). 
Supporting the descriptive utility of the mean/median population scores, we also 
evaluated the distribution of scores across patient groups.  Cumulative frequency plots 
for FACT-O, OCS, and EQ-5D showed that the distribution of scores was similar 
between arms at baseline and the distribution remained similar between arms over the 
course of the study (Figure 3). 
Dropout patterns had little effect on treatment differences in FACT-O or OCS 
mean summary scores.  In pattern-mixture models [4], patients were classified as either 
early dropouts (last visit at or before 25 weeks) or late dropouts (last visit after 25 
weeks).  For FACT-O, least squares adjusted mean for the treatment difference was 
−2.44 for early dropouts (n=614) and −1.65 for late dropouts (n=188). For OCS, it was 
−0.68 for early dropouts (n=623) and 0.17 for late dropouts (n=192). 
Associations Between Edema and HRQoL 
Incidence of edema was greater in the trebananib arm than in the placebo arm 
(any grade, 64% vs 28%; grade ≥3, 10% vs 1%).  In exploratory analyses, we examined 
the influence of treatment-emergent edema on FACT-O and OCS summary scores.  
Patients with grade ≥2 edema exhibited slightly larger decreases from baseline in FACT-
O and OCS scores compared with patients with grade 1 or no edema, but the scores 
were variable with no consistent pattern of compromised HRQoL among patients in the 
trebananib arm with grade ≥2 edema (Figure 4).  Overall, the data was not suggestive of 
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a differential influence of edema on FACT-O and OCS summary scores between 
treatment arms. 
 
Discussion 
The TRINOVA-1 study included a rigorous and systematic assessment of 
HRQoL.  Overall, these analyses demonstrated that the improvement in PFS and 
objective response rate among patients in the trebananib group [4] was achieved without 
compromising HRQoL.  The lack of influence of trebananib plus paclitaxel on HRQoL is 
an important finding because, in the absence of an unequivocal overall survival 
advantage (potentially due to long post-progression survival and the multiple lines of 
subsequent anticancer therapy administered), the objectives of treatment are to delay 
disease progression while minimizing potential negative effects of treatment-related 
toxicity.   
Our results represent one of the largest studies of HRQoL in patients with 
recurrent ovarian cancer receiving weekly paclitaxel.  Questionnaire completion rates 
were robust and consistent over time.  Distribution of patient scores was also similar 
over time, indicating that means were appropriate descriptors of aggregate out HRQoL 
across the study population.  We observed only small differences in outcomes across 
questionnaires that evaluated physical, social, emotional, and functional aspects of well-
being (FACT-O), symptoms specific to ovarian cancer (OCS), and global health status 
(EQ-5D).  Moreover, mean decrements in HRQoL scores from baseline appeared to be 
smaller than the established clinically important differences (FACT-O, six-point change 
[10]; EQ-5D, 0.06-point change in patients with cancer [13]).  Notably, the similarity in 
distribution of scores between the trebananib and placebo arms was observed 
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throughout the study suggesting that patients who remained in treatment did not 
experience reduced HRQoL as treatment continued.  Given that the patients’ baseline 
demographic characteristics suggested many had asymptomatic disease at study entry 
(eg, age, GOG performance status), improvements in HRQoL during treatment were not 
anticipated.  
Exploratory analyses suggested that incidence of treatment-emergent edema (an 
AE that occurs more frequently among patients receiving trebananib) [14] did not 
meaningfully alter patients’ HRQoL.  Most edema events occurring while patients were 
on-study were mild in severity (grade 1/2), and our analyses provide additional important 
information by assessing the patient perspective of edema and its impact on HRQoL.  
Although there was a suggestion of a small decrement in HRQoL among patients with 
edema, the relative magnitude of the questionnaires’ measurement sensitivity rather 
than a clinically meaningful finding. 
Importantly pattern-mixture models indicated patients in the trebananib and 
placebo arm who dropped out of the study during the earlier phase of treatment did not 
differ in their ratings of HRQoL.  This suggests that informative censoring due to removal 
of subjects from the population was unlikely to have obscured an unequal effect between 
treatment arms.  Missing data may raise significant questions of interpretation in 
investigations of HRQoL.  Consequently, any assumption that data are missing at 
random can result in underestimation of HRQoL effects.  Similarly, no differences in 
HRQoL were observed for those patients who remained in the study longer.  Together, 
these results suggest that the HRQoL outcomes identified in this study were not due to 
selective drop out of particular patient groups. 
Our results provide an informative comparison with results from studies 
evaluating the influence of the anti-VEGF monoclonal antibody bevacizumab on HRQoL 
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in patients with recurrent ovarian cancer.  In the open-label randomized AURELIA study, 
women with platinum-resistant ovarian cancer received paclitaxel, pegylated liposomal 
doxorubicin, or topotecan (investigator’s choice) with/without bevacizumab.  More 
patients in the bevacizumab arm (21.9%) than the chemotherapy-only arm (9.3%) rated 
their gastrointestinal and abdominal symptoms as improved in the bevacizumab arm 
after 8 weeks of treatment [15].  However, eligibility criteria for AURELIA allowed only 
patients with a PFI <6 months and excluded patients with a history of abdominal fistulae, 
gastrointestinal perforation, intra-abdominal abscess, or bowel obstruction  [16].  These 
exclusion criteria may have resulted in enrollment of a patient population for whom 
improvements in gastrointestinal symptoms would be more easily achieved.  It is also 
important to note that the primary analysis of HRQoL in AURELIA was conducted after 8 
weeks of treatment with an imbalance in patient numbers favoring the bevacizumab arm 
(122 patients versus 84 patients); few patients were evaluable at later timepoints, 
particularly in the chemotherapy only arm.  In the randomized placebo-controlled GOG-
0218 study of first-line therapy with carboplatin/paclitaxel with/without bevacizumab the 
combination improved PFS but was associated with a small reduction in HRQoL scores 
[17], although this difference was not maintained during bevacizumab maintenance 
therapy [18].  In the randomized open-label ICON7 study, first-line bevacizumab plus 
carboplatin/paclitaxel improved PFS [19] but was associated with a small decrement in 
HRQoL at 54 weeks [20].  These results illustrate the influence of toxicity profile and 
patient characteristics on HRQoL outcomes. 
Results from TRINOVA-1 suggest that the combination of trebananib plus 
paclitaxel compared with placebo plus paclitaxel does not compromise HRQoL in 
patients with platinum-resistant and partially platinum-sensitive recurrent ovarian cancer.  
The results of this study provide physicians with information that could guide clinical 
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decision making, particularly with respect to appropriate sequencing of antiangiogenic 
agents in women with recurrent ovarian cancer. 
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Figure Legends 
Figure 1. Instrument completion rates.  Data show proportion of patients with a 
completed questionnaire at each time point, with the denominator as the 
number of evaluable patients at that time point. 
Figure 2. Mean ± interquartile range (IQR) scores for (A) FACT-O, (B) OCS, and 
(C) EQ-5D scores over time. FACT-O, Functional Assessment of Cancer 
Therapy–Ovary; OCS, ovarian cancer–specific subscale. 
Figure 3. Cumulative frequency distribution plots for the (A) FACT-O, (B) OCS, and 
(C) EQ-5D at baseline, 9 weeks, and 25 weeks. FACT-O=Functional 
Assessment of Cancer Therapy–Ovary; OCS, ovarian cancer–specific 
subscale.  The shape of the distribution of scores for each instrument was 
similar at each time point, indicating that paclitaxel plus trebananib and 
paclitaxel plus placebo were not associated with major changes in the 
range of values. 
Figure 4. Mean ± SE (A) FACT-O and (B) OCS scores over time among patients 
classified as grade ≥2 edema and patients with grade 1 edema or without 
edema in the placebo arm (left panels) and trebananib arm (right panels) 
while on study.  FACT-O, Functional Assessment of Cancer Therapy–
Ovary; OCS, ovarian cancer–specific subscale. 
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Tables 
Table 1. Baseline Demographic and Clinical Characteristics 
 Intent-to-Treat Population Patient-Reported Outcomes Subset 
 
Trebananib 15 mg/kg + 
Paclitaxel 
(n = 461) 
Placebo 
+ Paclitaxel 
(n = 458) 
Trebananib 15 mg/kg 
+ Paclitaxel 
(n = 408) 
Placebo 
+ Paclitaxel 
(n = 426) 
Race/ethnicity, n (%) 
White  
Asian  
Black  
Other 
 
387 (84) 
58 (13) 
6 (1) 
10 (2) 
 
363 (79) 
82 (18) 
7 (2) 
6 (1) 
 
345 (85) 
47 (12) 
6 (1) 
10 (2) 
 
341 (80) 
74 (17) 
6 (1) 
5 (1) 
Region; n (%) 
Western Europe/Australia  
North America  
Rest of world 
 
193 (42) 
93 (20) 
175 (38) 
 
189 (41) 
91 (20) 
178 (39) 
 
169 (41) 
79 (19) 
160 (39) 
 
175 (41) 
83 (19) 
168 (39) 
Age, median (interquartile range), y 60 (51–66) 59 (50–65) 60 (51–66) 59 (50–65) 
GOG performance score, n (%) 
0 
1 
2 
 
259 (56) 
200 (43) 
2 (<1) 
 
252 (55) 
205 (45) 
1 (<1) 
 
239 (59) 
167 (41) 
2 (<1) 
 
238 (56) 
187 (44) 
1 (<1) 
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 Intent-to-Treat Population Patient-Reported Outcomes Subset 
 
Trebananib 15 mg/kg + 
Paclitaxel 
(n = 461) 
Placebo 
+ Paclitaxel 
(n = 458) 
Trebananib 15 mg/kg 
+ Paclitaxel 
(n = 408) 
Placebo 
+ Paclitaxel 
(n = 426) 
History of ascites at study entry, n 
(%) 
Yes 
No 
 
108 (23) 
353 (77) 
 
123 (27) 
335 (73) 
 
90 (22) 
318 (78) 
 
114 (27) 
312 (73) 
Primary tumor type, n (%) 
Ovarian cancer 
Primary peritoneal carcinoma 
Fallopian tube cancer 
  
423 (92) 
24 (5) 
14 (3) 
 
419 (92) 
24 (5) 
15 (3) 
 
373 (91) 
21 (5) 
14 (3) 
 
391 (92) 
21 (5) 
14 (3) 
Tumor histology, n (%) 
Serous 
Endometrioid 
Undifferentiated 
Transitional 
Other 
 
385 (84) 
29 (6) 
15 (3) 
4 (1) 
28 (6) 
 
388 (85) 
26 (6) 
10 (2) 
2 (<1) 
32 (7) 
 
341 (84) 
24 (6) 
14 (3) 
4 (1) 
25 (6) 
 
360 (85) 
25 (6) 
9 (2) 
2 (<1) 
30 (7) 
Histologic grade, n (%) 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
Unknown 
 
24 (5) 
69 (15) 
274 (59) 
94 (20) 
 
31 (7) 
84 (18) 
256 (56) 
87 (19) 
 
23 (6) 
65 (16) 
239 (59) 
81 (20) 
 
29 (7) 
81 (19) 
238 (56) 
78 (18) 
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 Intent-to-Treat Population Patient-Reported Outcomes Subset 
 
Trebananib 15 mg/kg + 
Paclitaxel 
(n = 461) 
Placebo 
+ Paclitaxel 
(n = 458) 
Trebananib 15 mg/kg 
+ Paclitaxel 
(n = 408) 
Placebo 
+ Paclitaxel 
(n = 426) 
Lines of prior anticancer  
therapy, n (%) 
1 
2 
3 
4 
Not available 
 
 
190 (41) 
174 (38) 
94 (20) 
2 (<1) 
1 (<1) 
 
 
172 (38) 
172 (38) 
114 (25) 
0 (0) 
0 (0) 
 
 
171 (42) 
154 (38) 
80 (20) 
2 (<1) 
1 (<1) 
 
 
155 (36) 
163 (38) 
108 (23) 
0 (0) 
0 (0) 
Platinum-free interval, n (%) 
≤6 months 
>6 and ≤12 months 
Primary platinum refractory 
 
235 (51) 
223 (48) 
3 (1) 
 
245 (53) 
212 (46) 
1 (<1) 
 
208 (51) 
198 (49) 
2 (<1) 
 
227 (53) 
198 (46) 
1 (<1) 
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